Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

173 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Management of Patients Undergoing CAR-T Cell Therapy in Germany.
Penack O, Dreger P, Ajib S, Ayuk F, Baermann BN, Bug G, Kriege O, Jentzsch M, Kobbe G, Koenecke C, Lutz M, Martin S, Schlegel PG, Schroers R, von Tresckow B, Vucinic V, Subklewe M, Bethge W, Wolff D. Penack O, et al. Oncol Res Treat. 2024;47(3):65-75. doi: 10.1159/000536201. Epub 2024 Jan 10. Oncol Res Treat. 2024. PMID: 38198763 Free PMC article.
ERS/EBMT clinical practice guidelines on treatment of pulmonary chronic graft-versus-host disease in adults.
Bos S, Murray J, Marchetti M, Cheng GS, Bergeron A, Wolff D, Sander C, Sharma A, Badawy SM, Peric Z, Piekarska A, Pidala J, Raj K, Penack O, Kulkarni S, Beestrum M, Linke A, Rutter M, Coleman C, Tonia T, Schoemans H, Stolz D, Vos R. Bos S, et al. Among authors: penack o. Eur Respir J. 2024 Mar 28;63(3):2301727. doi: 10.1183/13993003.01727-2023. Print 2024 Mar. Eur Respir J. 2024. PMID: 38485149
Patient engagement in hematopoietic stem cell transplantation and cell therapy: a survey by the EBMT patient engagement task force & transplantation complications working party.
Schoemans H, Burns LJ, Liptrott SJ, Murray J, Kenyon M, Barata A, Bolaños N, Scholl I, Hamilton B, Phelan R, Buchbinder D, Penack O, Moiseev I, Boreland W, Peczynski C, De Geest S, Sureda A, Snowden JA, Shaw B, Peric Z, Kroeger N. Schoemans H, et al. Among authors: penack o. Bone Marrow Transplant. 2024 Sep;59(9):1286-1294. doi: 10.1038/s41409-024-02290-7. Epub 2024 Jun 18. Bone Marrow Transplant. 2024. PMID: 38890544
Long-Term Survivors after Failure of Chimeric Antigen Receptor T Cell Therapy for Large B Cell Lymphoma: A Role for Allogeneic Hematopoietic Cell Transplantation? A German Lymphoma Alliance and German Registry for Stem Cell Transplantation Analysis.
Derigs P, Bethge WA, Krämer I, Holtick U, von Tresckow B, Ayuk F, Penack O, Vucinic V, von Bonin M, Baldus C, Mougiakakos D, Wulf G, Schnetzke U, Stelljes M, Fante M, Schroers R, Kroeger N, Dreger P; German Lymphoma Alliance and the German Registry for Stem Cell Transplantation. Derigs P, et al. Among authors: penack o. Transplant Cell Ther. 2023 Dec;29(12):750-756. doi: 10.1016/j.jtct.2023.09.008. Epub 2023 Sep 13. Transplant Cell Ther. 2023. PMID: 37709204
Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality.
Rejeski K, Wang Y, Hansen DK, Iacoboni G, Bachy E, Bansal R, Penack O, Müller F, Bethge W, Munoz J, Mohty R, Bücklein VL, Barba P, Locke FL, Lin Y, Jain MD, Subklewe M. Rejeski K, et al. Among authors: penack o. Blood Adv. 2024 Apr 23;8(8):1857-1868. doi: 10.1182/bloodadvances.2023011767. Blood Adv. 2024. PMID: 38181508 Free PMC article.
Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use.
Bücklein V, Perez A, Rejeski K, Iacoboni G, Jurinovic V, Holtick U, Penack O, Kharboutli S, Blumenberg V, Ackermann J, Frölich L, Johnson G, Patel K, Arciola B, Mhaskar R, Wood A, Schmidt C, Albanyan O, Gödel P, Hoster E, Bullinger L, Mackensen A, Locke F, von Bergwelt M, Barba P, Subklewe M, Jain MD. Bücklein V, et al. Among authors: penack o. Hemasphere. 2023 Jul 11;7(8):e907. doi: 10.1097/HS9.0000000000000907. eCollection 2023 Aug. Hemasphere. 2023. PMID: 37449196 Free PMC article.
Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion.
Rejeski K, Perez A, Iacoboni G, Blumenberg V, Bücklein VL, Völkl S, Penack O, Albanyan O, Stock S, Müller F, Karschnia P, Petrera A, Reid K, Faramand R, Davila ML, Modi K, Dean EA, Bachmeier C, von Bergwelt-Baildon M, Locke FL, Bethge W, Bullinger L, Mackensen A, Barba P, Jain MD, Subklewe M. Rejeski K, et al. Among authors: penack o. Sci Adv. 2023 Sep 22;9(38):eadg3919. doi: 10.1126/sciadv.adg3919. Epub 2023 Sep 22. Sci Adv. 2023. PMID: 37738350 Free PMC article.
Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study.
Ortí G, Peczynski C, Boreland W, O'Reilly M, von Bonin M, Balduzzi A, Besley C, Kalwak K, Ryhänen S, Güngör T, Wynn RF, Bader P, Mielke S, Blaise D, Amrolia P, Yakoub-Agha I, Calkoen F, Schubert ML, Potter V, Pichler H, Kröger N, Kwon M, Sengeloev H, Torrent A, Chalandon Y, van Gorkom G, Koenecke C, Graham C, Schoemans H, Moiseev I, Penack O, Peric Z. Ortí G, et al. Among authors: penack o. Leukemia. 2024 Nov 19. doi: 10.1038/s41375-024-02467-5. Online ahead of print. Leukemia. 2024. PMID: 39562721
173 results